ZKSCAN3 and carcinoma: Overall, ZKSCAN3 was immunoreactive in 51 (34%) of 150 benign, 92 (63%) of 146 high-grade PIN (HGPIN), and 279 (93%) of 300 carcinoma tissues (Table 2).